Radar · Immunotherapy in California
Best Immunotherapy Companies in California, United States
The 327 best Immunotherapy companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Halozyme.
By Riya SenguptaFinancials
327companies tracked
$23.4Bdisclosed funding
0unicorns
242have raised
FLIAR INTELLIGENCE · IMMUNOTHERAPY × CALIFORNIA
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
69%cloud-native stacks
2025funding peak (by rounds)
2017median founding year
42median Fliar Index™
420kcombined LinkedIn audience
43%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Immunotherapy companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Developer of drug delivery technologies for the treatment of various diseases | $1.3B | 46 mo ago | 373 373 → 536 (+44%) · sector median +7% | Helen Torley CEO & President | WordPressBugHerdApple iCloud Mail+21 | 715 patents Enabling subcutaneous delivery of biologics via hyaluronidase and advanced injector devices | 1 partnership |
| 2 | ImmunityBio Developer of peptide-based vaccines for immunotherapy | $1.1B | 29 mo ago | 725 725 → 657 (-9%) · sector median +7% | Richard Adcock Chief Executive Officer | WordPressApple iCloud MailMySQL+41 | 499 patents Cell-based cancer immunotherapies and therapeutic vaccines targeting solid tumors. | 2 job openings · 1 partnership |
| 3 | Summit Developer of therapeutics for oncology and rare diseases 22Partners top 31%Funding top 33%Product top 35%News top 37% All 13 signals ▾Partnerstop 31% Fundingtop 33% Producttop 35% Newstop 37% Techtop 45% Growthbottom 43% Moatbottom 43% Marketbottom 42% Talentbottom 41% Globalbottom 37% Patentsbottom 30% Innovationbottom 26% Fin. healthbottom 22% Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $713M | 7 mo ago | 99 | Maky Zanganeh CEO | WordPress Block EditorWordPressMySQL+18 | 13 patents Digital media submission, processing, and distribution platforms for online content management. | — |
| 4 | Allogene Therapeutics Developer of chimeric antigen receptor cell therapy to treat cancer | $532M | 25 mo ago | 303 303 → 215 (-29%) · sector median +7% | David Chang President and Chief Executive Officer | WordPressMySQLPHP+25 | 414 patents Engineering allogeneic CAR‑T cells with immune‑evasion, switch receptors, and dosing technologies | 3 launchs |
| 5 | Lyell Immunopharma Developer of CAR- T therapy for cancer treatment 45Patents top 14%Innovation top 21%Funding top 24%Talent top 28% All 11 signals ▾Patentstop 14% Innovationtop 21% Fundingtop 24% Talenttop 28% Techtop 30% Moatbottom 46% Globalbottom 42% Marketbottom 32% Growthbottom 32% Newsbottom 23% Fin. healthbottom 18% Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $493M | 10 mo ago | 224 224 → 233 (+4%) · sector median +7% | Stan Riddell Co-Founder | WordPressMySQLPHP+16 | 163 patents Patents concentrated in chemistry & materials | — |
| 6 | Inhibrx Antibody-based immunotherapeutics for cancer and infectious diseases 45Funding top 25%Patents top 29%Product top 32%Innovation top 33% All 11 signals ▾Fundingtop 25% Patentstop 29% Producttop 32% Innovationtop 33% Techtop 42% Moatbottom 49% Growthbottom 43% Marketbottom 41% Globalbottom 40% Newsbottom 32% Fin. healthbottom 31% Funding: Raised $469M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Patents: 499 patents matched (strict assignee match) · 161 filings since 2022 vs 269 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $469M | 15 mo ago | 112 112 → 111 (-1%) · sector median +7% | — | WordPressBugHerdMySQL+34 | 499 patents Engineering multispecific therapeutic proteins (antibodies, DR5, serpin fusions) for immune modulation | 1 launch |
| 7 | TORL BioTherapeutics Developer of antibody-based therapeutics for the treatment of cancer 37Funding top 16%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 37/100 | $350M | 8 mo ago | — | Mark Attanasio Co-Founder | — | — | — |
| 8 | Capstan Therapeutics Developer of cell therapies for a broad range of diseases | $340M | 27 mo ago | 75 | Laura Shawver CEO | WordPressTypeScriptGraphQL+21 | — | — |
| 9 | Poseida Therapeutics Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | $324M | 34 mo ago | 259 | — | WordPressMySQLPHP+18 | 426 patents Patents concentrated in chemistry & materials | — |
| 10 | Kyverna Therapeutics Developer of T-cell therapy for autoimmune disease | $322M | 34 mo ago | 96 96 → 160 (+67%) · sector median +7% | — | DrupalApple iCloud MailMicrosoft 365+29 | — | — |
| 11 | CG Oncology Developer of immunotherapeutic agents for treating cancer | $294M | 34 mo ago | 45 | — | DrupalApple iCloud MailMicrosoft 365+28 | 149 patents Novel anti‑cancer small molecules and CAR therapies targeting EMT and AXL/ROR2 receptors | — |
| 12 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | 949 | Henry Ji Co-Founder & CEO | — | 1,073 patents Patents concentrated in health & consumer products | — |
| 13 | BlossomHill Therapeutics Provider of the drug for the treatment of oncology and autoimmune disorders 55Funding top 20%Patents top 21%Innovation top 23%Moat top 26% All 7 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 23% Moattop 26% Newsbottom 42% Globalbottom 42% Marketbottom 34% Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $260M | 6 mo ago | 14 | — | — | 133 patents Patents concentrated in chemistry & materials | 3 job openings |
| 14 | Asher Biotherapeutics Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $218M | 26 mo ago | 48 | Ivana Djuretic Founder | — | 78 patents Patents concentrated in chemistry & materials | — |
| 15 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 3 mo ago | — | Ken Song CEO | WordPressMySQLPHP+15 | — | — |
| 16 | Eledon Provider of therapeutics solution for organ or cellular transplantation in autoimmune and neurodegenerative… | $201M | 25 mo ago | 17 17 → 42 (+147%) · sector median +7% | — | DrupalApple iCloud MailMicrosoft 365+24 | — | — |
| 17 | Attralus Developer of drugs for the treatment of Amyloid diseases | $197M | 28 mo ago | 23 | Jonathan Wall Co-Founder | — | 50 patents Engineered Fc‑fusion and antibody‑peptide biologics for amyloid disease therapy | — |
| 18 | Solve Therapeutics Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment 55Funding top 16%Moat top 40%Global top 45%Market bottom 49% All 5 signals ▾Fundingtop 16% Moattop 40% Globaltop 45% Marketbottom 49% Talentbottom 49% Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 55/100 | $195M | 7 mo ago | — | Dave Johnson Founder & CEO | — | — | — |
| 19 | Spyre Therapeutics Developer of monoclonal antibody therapeutics for inflammatory bowel disease | $180M | 30 mo ago | 30 | Cameron Turtle CEO | DrupalApple iCloud MailPHP+22 | — | 1 award |
| 20 | Santa Ana Bio Developer of precision medicines for autoimmune diseases. | $168M | 25 mo ago | 25 | Danny Wells Co-Founder | — | — | — |
| 21 | Attovia Developer of antibody-based therapeutics for immune-mediated diseases and oncology 48Funding top 19%Talent top 28%Moat top 38%Global bottom 38% All 5 signals ▾Fundingtop 19% Talenttop 28% Moattop 38% Globalbottom 38% Marketbottom 37% Funding: Raised $165M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $165M | 14 mo ago | — | Zaneta Odrowaz Co-Founder | — | — | — |
| 22 | Nura Bio Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines | $141M | 21 mo ago | 25 | Marc Freeman Co-Founder | — | — | — |
| 23 | Arthrosi Therapeutics Developer of therapeutics for gout, chronic kidney diseases, and oncology 22Funding top 26%News top 46%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 26% Newstop 46% Moattop 48% Talentbottom 49% Techbottom 43% Globalbottom 37% Marketbottom 24% Funding: Raised $140M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) News: 2 BI events in 12 mo (of 6 tracked, 3 types) · +100% YoY rank vs industry peers · Fliar Intelligence Index 22/100 | $140M | 12 mo ago | 11 | Litain Yeh Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+24 | — | — |
| 24 | Ouro Medicines Developer of therapeutics for people living with chronic immune-mediated diseases | $120M | 17 mo ago | — | Jaideep Dudani CEO | — | — | — |
| 25 | STAR Therapeutics Developer of antibody therapies for multiple diseases 40Funding top 21%Moat top 42%Talent bottom 49%News bottom 45% All 6 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Newsbottom 45% Marketbottom 42% Globalbottom 38% Funding: Raised $90.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $90M | 8 mo ago | 43 | Adam Rosenthal Founder & CEO | — | — | — |
| 26 | TEMPEST THERAPEUTICS Developing targeted, immune-mediated oral cancer therapies for broad patient benefit 21Funding top 28%News top 36%Growth top 42%Tech top 49% All 9 signals ▾Fundingtop 28% Newstop 36% Growthtop 42% Techtop 49% Moatbottom 43% Talentbottom 41% Globalbottom 39% Marketbottom 23% Fin. healthbottom 13% Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $88M | 2 mo ago | 19 | Stephen B Chief Executive Officer | DrupalPHPparticles.js+25 | — | — |
| 27 | Azalea Therapeutics Developer of precision genome engineering technologies for in vivo cell therapies 62Talent top 23%Funding top 26%Global bottom 33% All 3 signals ▾Talenttop 23% Fundingtop 26% Globalbottom 33% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated Funding: Raised $82.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 7 mo ago | — | Jenny H Co-Founder | — | — | 1 expansion |
| 28 | Cidara Therapeutics Developer of novel anti-infectives for infectious diseases (bacterial and fungal) | $78M | 18 mo ago | 90 90 → 48 (-47%) · sector median +7% | Jeff Stein CEO | — | 275 patents Antibody‑drug conjugates and biologics targeting viral and cancer pathways. | — |
| 29 | Tr1X Developer of T cell-based products to treat autoimmune and inflammatory diseases | $75M | 14 mo ago | 7 | David Vries Co-Founder | — | 35 patents IL-10‑secreting CD4+ CAR‑T cell immunotherapies for enhanced immune regulation | — |
| 30 | EpiBiologics Developer of antibody-based targeted therapies to treat multiple diseases 45Funding top 21%Talent top 38%Moat top 39%Innovation top 42% All 7 signals ▾Fundingtop 21% Talenttop 38% Moattop 39% Innovationtop 42% Patentstop 42% Globalbottom 37% Marketbottom 34% Funding: Raised $73.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $73M | 5 mo ago | 22 | Josef Gramespacher Co-Founder | — | 13 patents Bispecific antibody therapeutics for targeted degradation of EGFR and cMET receptors | 1 job opening |
| 31 | Vivace Therapeutics Developer of cancer therapeutics targeting a novel cancer pathway | $70M | 15 mo ago | 6 | — | — | — | 1 job opening |
| 32 | Link Cell Therapies Developer of CAR-T cell therapies for the treatment of cancer 11Funding top 29%Tech bottom 41%Global bottom 29%Market bottom 19% All 4 signals ▾Fundingtop 29% Techbottom 41% Globalbottom 29% Marketbottom 19% Funding: Raised $60.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) Tech: 19 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 6 mo ago | 8 | — | WordPress Block EditorWordPressMySQL+16 | — | — |
| 33 | CERo Therapeutics Developer of platforms for cellular immunotherapy | $56M | 13 mo ago | 15 15 → 16 (+7%) · sector median +7% | — | Node.jsUbuntuBootstrap+15 | — | — |
| 34 | LTZ Therapeutics Developer of immunotherapies to treat cancer and other diseases 35Funding top 26%Moat top 39%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 39% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $47M | 1 mo ago | 23 | Martin Treder Co-Founder | — | — | — |
| 35 | Primmune Therapeutics Developer of immunotherapies for treating cancer 42Funding top 21%Talent top 28%Product top 35%Innovation top 38% All 8 signals ▾Fundingtop 21% Talenttop 28% Producttop 35% Innovationtop 38% Moattop 39% Techbottom 40% Globalbottom 36% Marketbottom 26% Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) Talent: Analyst team rating 4/5 · 4 named leaders on record rank vs industry peers · Fliar Intelligence Index 42/100 | $47M | 4 mo ago | 9 | Stephen Webber Co-Founder | — | — | — |
| 36 | BriaCell Therapeutics Developer of immunotherapies for the treatment of cancer | $46M | 17 mo ago | 16 16 → 24 (+50%) · sector median +7% | — | WordPressPleskMySQL+22 | — | 3 job openings · 2 partnerships |
| 37 | PeproMene Bio Developer of T-cell therapeutics for cancer treatment | $44M | 17 mo ago | 6 | — | WordPressMySQLPHP+15 | — | — |
| 38 | Calidi Biotherapeutics Developer of gene therapies for the treatment of cancer and other indications | $34M | 22 mo ago | 29 29 → 31 (+7%) · sector median +7% | Megan Camaisa Co-Founder | WebflowApple iCloud MailMicrosoft 365+15 | 47 patents Oncolytic viral therapies using cell carriers and engineered smallpox vaccine platforms | 1 launch |
| 39 | Equillium Developer of therapies for treating autoimmune and inflammatory disorders | $30M | 10 mo ago | 36 36 → 38 (+6%) · sector median +7% | Daniel Bradbury Co-Founder & CEO | Q4MediaElement.jsMicrosoft ASP.NET+14 | 33 patents Immunotherapy antibodies targeting CD6 for autoimmune and inflammatory disease treatment | — |
| 40 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | 3 | — | — | 26 patents Patents concentrated in chemistry & materials | — |
| 41 | Vironexis Biotherapeutics Developer of AAV-delivered T-cell immunotherapies for the treatment of cancer | $26M | 21 mo ago | — | Timothy Cripe Co-Founder | — | 15 patents AAV-based gene therapy vectors targeting metastatic cancer prevention and treatment | — |
| 42 | cTRL Therapeutics Developer of therapeutics for solid tumor treatments | $19M | 20 mo ago | — | Shana Kelley Founder | — | — | — |
| 43 | RyboDyn Developer of immunotherapies for the treatment of cancer 21Talent top 28%Funding top 37%Global bottom 48%Market bottom 15% All 4 signals ▾Talenttop 28% Fundingtop 37% Globalbottom 48% Marketbottom 15% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 2 mo ago | 3 | Kerry Wilson Co-Founder | — | — | — |
| 44 | ImmuneBridge Developer of allogeneic cellular medicines to treat cancer | $12M | 14 mo ago | 4 | Jesse Cotari Co-Founder | — | 10 patents Patents concentrated in health & consumer products | — |
| 45 | Trellis Bioscience Human antibodies against infectious diseases and cancer | $10M | 14 mo ago | 6 | Stefan Ryser President & CEO | — | 170 patents Antibody-based therapeutics and vaccines targeting RSV and influenza viral proteins. | — |
| 46 | Nuravax Developer of immunotherapy for neurodegenerative disorders | $3M | 13 mo ago | — | Roman Kniazev Chief Executive Officer | — | — | — |
| 47 | ESTRELLA BIOPHARMA Developer of immunotherapies for cancer treatment | $3M | 12 mo ago | — | Cheng Liu CEO | — | — | — |
| 48 | Bio Usawa Developer of immunotherapy for cancer treatment | $3M | 7 mo ago | — | Richard Chin Co-Founder | BootstrapSlickjQuery+9 | — | — |
| 49 | Acumen Pharmaceuticals Developer of monoclonal antibody therapeutics for Alzheimer's disease | $2M | 3 mo ago | 52 52 → 67 (+29%) · sector median +7% | — | DrupalApple iCloud MailMicrosoft 365+22 | — | 1 partnership |
| 50 | Aarvik Therapeutics Developer of antibody-drug conjugates for oncology targets | $1M | 8 mo ago | 9 | Sachdev Sidhu Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+10 | — | — |
Top 12 Immunotherapy companies in California
#1
Public · Menlo Park, California · founded 2003 · 99 employees$713Mraised▾
Public · Menlo Park, California · founded 2003 · 99 employees
Developer of therapeutics for oncology and rare diseases. It offers Ivonescimab which combines the effects of immunotherapy via a blockade of PD-1 with the anti-VEGF effect for the treatment of non-small cell lung cancer.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Partners
top 31%Funding
top 33%Product
top 35%News
top 37%Tech
top 45%Growth
bottom 43%Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals
Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Post IPO (Oct 2025)
Product: 0 product launch events in 12 mo, 1 the year before · Company stage: Public
Audience (LinkedIn): 58k LinkedIn followers — 13.8% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$228M
- Sep 2024Post IPO$235M
- Jun 2024Post IPO$200M
- Nov 2020Post IPO$50M
Founders & team
Investors
Akeso
Tech stack
CloudflareFancyboxGodaddyGoogle Font ApiHstsJquery
#2
Acquired · San Diego, California · founded 2024$206.2Mraised▾
Acquired · San Diego, California · founded 2024
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Growth
top 38%News
top 48%Moat
top 48%Talent
bottom 49%Tech
bottom 38%Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series E (Mar 2026)
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 8 tracked, 2 types) · +0% YoY · Top themes: M&A
Audience (LinkedIn): 9k LinkedIn followers — 2.0% of this cohort's audience
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Mar 2026Series E$505M
- Sep 2024Series D$370M
Founders & team
Investors
Venrock, Fairmont, TCG Crossover, VenBio, Foresite Capital, Third Rock Ventures
Tech stack
CloudflareCloudflare Bot ManagementDreamhostGoogle Font ApiHttp/3Jquery
#3
Public · San Francisco, California · founded 2011 · 19 employees$88.2Mraised▾
Public · San Francisco, California · founded 2011 · 19 employees
Developing targeted, immune-mediated oral cancer therapies for broad patient benefit. This clinical-stage biotechnology company focuses on creating small molecule therapeutics to treat cancer. Their approach involves mechanisms that directly target and kill tumor cells while simultaneously activating the body's own tumor-specific immunity. The company is developing first-in-class oral drug therapeutics with the potential to offer significant advantages to a wide range of cancer patients. They explore both new and validated pathways to discover and develop novel therapeutics. Their pipeline represents innovative approaches to cancer treatment, aiming to improve patient outcomes through targeted and immune-mediated strategies. The company's focus is on oncology drug discovery and development, with the goal of advancing novel therapeutics that will bring meaningful benefit to patients.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 28%News
top 36%Growth
top 42%Tech
top 49%Moat
bottom 43%Talent
bottom 41%Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) · Last round Post IPO (Mar 2026)
News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Web rank 5,000,000 → 10,000,000 YoY · 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Funding rounds
- Mar 2026Post IPO$6M
- Mar 2026Post IPO$2M
- Feb 2020Series B$83.2M
- 2015Series A—
Founders & team
Investors
F-Prime Capital, Lilly Asia Ventures, Foresite Capital, Eight Roads Ventures, Versant Ventures, Quan Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#4
Series B · Redwood City, California · founded 2021 · 23 employees$47Mraised▾
Series B · Redwood City, California · founded 2021 · 23 employees
Developer of immunotherapies to treat cancer and other diseases. The company focuses on the development of immunotherapies that are capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science technology.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Moat
top 39%Talent
bottom 49%Market
bottom 40%Global
bottom 36%Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Finance Coordinator (R&D), Medical/Sr. Med Director (MD) – Early Clinical Development
Activity (LinkedIn): 1 partnerships (incl. GlisoSmithKline (GSK)) announced in 12 mo
Funding rounds
- May 2026Series B$38M
- Jul 2024Series A$20M
- May 2023Seed$10M
- Apr 2022Seed$17M
Founders & team
Investors
Qiming Venture Partners, Shunwei Capital, K2 Venture Capital, Tigermed, Lapam Capital, K2VC
#5
Series B · San Diego, California · founded 2020 · 14 employees$259.6Mraised▾
Series B · San Diego, California · founded 2020 · 14 employees
Provider of the drug for the treatment of oncology and autoimmune disorders. The company is involved in drug design and development based on small molecules.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 23%Moat
top 26%News
bottom 42%Global
bottom 42%Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (Nov 2025)
Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Innovation: 133 patents (top 21% of patent-holders) · 133 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 9k LinkedIn followers — 2.2% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Principal Programmer, Statistical Programming, Director/Senior Director, Medical Affairs
Funding rounds
- Nov 2025Series B$84.2M
- Dec 2023Series B$100M
- Mar 2021Series A$71M
Investors
Cormorant Asset Management, Orbimed, Vivo Capital, Colt Ventures, Plaisance Capital Management, H&D Asset Management
#6
Acquired · San Francisco, California · founded 2011 · 3 employees$26.7Mraised▾
Acquired · San Francisco, California · founded 2011 · 3 employees
Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 28%Moat
top 32%Patents
bottom 48%Global
bottom 42%Innovation
bottom 33%Market
bottom 18%Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents
Patents: 26 patents matched (strict assignee match) · 4 filings since 2022 vs 12 in 2017-21 · Latest publication 2023
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2022Series A$3.5M
- Nov 2020Conventional Debt$250K
- Sep 2020Series A$3.2M
- Jan 2020Grant (prize money)$300K
Investors
National Cancer Institute, Connecticut Innovations, Navation, KICC, HHS, JLABS
#7
Series C · Los Angeles, California · founded 2019$350Mraised▾
Series C · Los Angeles, California · founded 2019
Developer of antibody-based therapeutics for the treatment of cancer. The company's lead candidate, TORL-1-23, is a CLDN6-directed antibody-drug conjugate for patients across multiple cancer types. Also, it is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 16%Moat
top 31%Talent
bottom 49%Market
bottom 40%Global
bottom 29%Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series C (Oct 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Oct 2025Series C$96M
- Apr 2024Series B$158.3M
- Apr 2023Series B$158M
Founders & team
Investors
Goldman Sachs Asset Management, Deep Track Capital, Moore Ventures, Cowen, Bristol-Myers Squibb, Vertex Ventures HC
#8
Series D · San Diego, California · founded 2021$195Mraised▾
Series D · San Diego, California · founded 2021
Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment. The company focuses on advancing antibody-based therapeutics to address unmet medical needs. It refines a chemistry platform while developing targeted radionuclide therapeutics. The company evaluates companion radiodiagnostics for use with other types of targeted cancer therapeutics.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 16%Moat
top 40%Global
top 45%Market
bottom 49%Talent
bottom 49%Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series D (Nov 2025)
Moat: Soonicorn · 10 curated direct competitors tracked
Global: Investors from 3 countries beyond United States
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Nov 2025Series D$120M
- Dec 2024Series C$75M
Founders & team
Investors
Yosemite, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck
#9
Public · San Francisco, California · founded 2018 · 224 employees$493Mraised▾
Public · San Francisco, California · founded 2018 · 224 employees
Developer of CAR- T therapy for cancer treatment. The lead CAR program LYL797is developed for the treatment of ROR1+ non-small cell lung cancer and triple-negative breast cancer. Another candidate LYL845 is an autologous TIL therapy for the treatment of multiple solid tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Patents
top 14%Innovation
top 21%Funding
top 24%Talent
top 28%Tech
top 30%Moat
bottom 46%Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 · Latest publication 2026
Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21
Funding: Raised $493M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) · Last round Post IPO (Jul 2025)
Audience (LinkedIn): 22k LinkedIn followers — 5.1% of this cohort's audience
Funding rounds
- Jul 2025Post IPO$100M
- Mar 2020Series C$493M
- 2018Seed—
Founders & team
Investors
GSK, Sahsen Ventures, 8VC, Foresite Capital, Arch Venture Partners, Mubadala
Tech stack
Amazon Web ServicesBootstrapCloudflareCloudflare Bot ManagementFont AwesomeGoogle Analytics
#10
Series B · San Diego, California · founded 2017 · 9 employees$46.8Mraised▾
Series B · San Diego, California · founded 2017 · 9 employees
Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Talent
top 28%Product
top 35%Innovation
top 38%Moat
top 39%Tech
bottom 40%Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) · Last round Series B (Jan 2026)
Talent: Analyst team rating 4/5 · 4 named leaders on record · 4 C-suite/founder profiles curated
Product: 3 distinct product lines · Company stage: Series B
Funding rounds
- Jan 2026Series B$8.6M
- Nov 2021Series A$8.4M
- Jan 2021Series A$4M
- Oct 2020Series A$27.4M
Founders & team
Investors
CAM Capital, BioBrit, BioRock Ventures, Bioqube Ventures, Polaris Partners, Samsara BioCapital
Tech stack
WordpressMysqlPhpDownload MonitorContact Form 7Yoast Seo
#11
Series B · San Carlos, California · founded 2021 · 22 employees$73Mraised▾
Series B · San Carlos, California · founded 2021 · 22 employees
Developer of antibody-based targeted therapies to treat multiple diseases. The company has a proprietary EpiTAC platform that enables the development of first-in-class and best-in-class targeted therapies that degrade disease-driving membrane and extracellular proteins against a wide range of disorders.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 21%Talent
top 38%Moat
top 39%Innovation
top 42%Patents
top 42%Global
bottom 37%Funding: Raised $73.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents · Soonicorn
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Mass Spec Scientist Large Molecule Characterization
Funding rounds
- Jan 2026Series B$107M
- Jul 2023Series A$23M
- Mar 2023Series A$50M
Founders & team
Investors
Mubadala, Polaris Partners, Vivo Capital, Google Ventures, Digitalis Ventures, Taiho Ventures
#12
Acquired · Solana Beach, California · founded 2009 · 112 employees$468.6Mraised▾
Acquired · Solana Beach, California · founded 2009 · 112 employees
Antibody-based immunotherapeutics for cancer and infectious diseases. it has proprietary platforms that enable fit-for-function bio-therapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. Its product pipeline includes INBRX-109 an engineered tetravalent sdAb-based therapeutic candidate to induce tumor selective programmed cell death, and INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 to treat locally advanced or metastatic solid tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 25%Patents
top 29%Product
top 32%Innovation
top 33%Tech
top 42%Moat
bottom 49%Funding: Raised $469M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) · Last round Grant (prize money) (Mar 2025)
Patents: 499 patents matched (strict assignee match) · 161 filings since 2022 vs 269 in 2017-21 · Latest publication 2026
Product: 3 distinct product lines · Company stage: Acquired
Audience (LinkedIn): 7k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2025Grant (prize money)$120.1K
- Sep 2023Post IPO$200M
- Feb 2021Grant (prize money)$279.4K
- Apr 2020Conventional Debt$10M
Investors
Oxford Finance, Viking Global Investors, HHS, Military Health, RA Capital Management, Alexandria
Tech stack
AccessibeAdobe Experience Platform LaunchAmplitudeAosBabelBugherd
Funding & investor landscape
$23.4Btotal disclosed funding
238companies funded
979disclosed rounds
3rounds last 90 days
Most active investors
Notable founders
Maky Zanganeh
CEO · Summit
Ken Song
CEO · Candid Therapeutics
Stephen B
Chief Executive Officer · TEMPEST THERAPEUTICS
Martin Treder
Co-Founder · LTZ Therapeutics
Mark Attanasio
Co-Founder · TORL BioTherapeutics
Dave Johnson
Founder & CEO · Solve Therapeutics
Stan Riddell
Co-Founder · Lyell Immunopharma
Crystal Mackall
Co-Founder · Lyell Immunopharma
Stephen Webber
Co-Founder · Primmune Therapeutics
James Appleman
Co-Founder & CSO · Primmune Therapeutics
Josef Gramespacher
Co-Founder · EpiBiologics
Ann Lee-Karlon
CEO · EpiBiologics
Prism market signals · United States · country-scoped Prism corpus, 1,146,706 docs
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Immunology in California is moving
A read on the academic research around Immunology in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 922 papers.
UC Los Angeles, San Francisco, and San Diego lead California's immunology research, dominated by CAR-T and cancer immunotherapy themes, with a cautiously optimistic tone (stance 0.47).
922 papers · stance +0.47 · 32% breakthrough · 17% concern
top institutions
- University of California, Los Angeles180
- University of California, San Francisco175
- University of California San Diego137
- University of Southern California86
- University of California, Irvine69
leading researchers
Yan-Ruide Li · Huang, Alexander · Wang, Guanning · Yuning Chen · Antoni Ribas · Wenxue Ma
prism intelligence · tone & topics
93% positive · 2% critical tone
PharmaceuticalsBiotechnologyClinical TrialsMedical ResearchHealthOncology
▲
Breakthroughs257 · 28%
28%→28% share
▲1.0× share momentum0 median citations86% since 2021mostly methods-led
Immunotherapy breakthroughs are surging — papers rose from 11 to 98, now dominating California immunology research.
rising sub-themes (early→recent)
- Immunotherapy11→98
- Immune system5→92
- Chimeric antigen receptor6→42
- Cancer immunotherapy1→37
- Tumor microenvironment1→29
Newly emergingT cell 0→22 · Antibody 0→10 · Autoimmunity 0→9
Landmark Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression · 1,859 cites
◆
Advancements414 · 45%
▼ 51%→45% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Immune system advancements intensified sharply — papers scaled from 13 to 130, leading all advancement sub-topics.
rising sub-themes (early→recent)
- Immune system13→130
- Immunotherapy19→134
- Cancer5→61
- Tumor microenvironment3→42
- Immune checkpoint2→37
Newly emergingT cell 0→19 · Prostate cancer 0→15 · Clinical trial 0→15
Landmark Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck · 4,969 cites
▼
Concerns142 · 15%
▲ 14%→15% share
▲1.1× share momentum0 median citations85% since 2021mostly reviews
Immunotherapy safety concerns are escalating — related papers jumped from 4 to 56, with Pembrolizumab newly flagged.
rising sub-themes (early→recent)
- Immunotherapy4→56
- Immune system5→42
- Cancer1→20
- Tumor microenvironment1→19
- Chimeric antigen receptor1→16
Newly emergingCancer immunotherapy 0→11 · Immune checkpoint 0→10 · Pembrolizumab 0→9
Landmark Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Pat · 635 cites
Common questions
How many Immunotherapy companies are there in California, United States?
Radar tracks 327 indexable Immunotherapy companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Immunotherapy companies in California, United States?
The Immunotherapy companies in California, United States on this list have raised a combined $23.4B in disclosed equity funding across 238 funded companies.
Which is the highest-funded Immunotherapy company in California, United States?
Halozyme is the highest-funded Immunotherapy company in California, United States, with $1.3B in disclosed equity funding.
How many Immunotherapy companies in California, United States are funded?
238 of the 327 Immunotherapy companies in California, United States on this list have disclosed at least one equity funding round.
How many Immunotherapy unicorns are there in California, United States?
None of the Immunotherapy companies in California, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in California, United States Immunotherapy companies?
The most active investors in California, United States Immunotherapy companies on this list include HHS, Orbimed, Janus Henderson Investors, RA Capital Management, Foresite Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.